MA50398A - Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma - Google Patents
Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gammaInfo
- Publication number
- MA50398A MA50398A MA050398A MA50398A MA50398A MA 50398 A MA50398 A MA 50398A MA 050398 A MA050398 A MA 050398A MA 50398 A MA50398 A MA 50398A MA 50398 A MA50398 A MA 50398A
- Authority
- MA
- Morocco
- Prior art keywords
- pi3k
- substituted
- hydroxy groups
- imidazole derivatives
- gamma inhibitors
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- -1 HYDROXY GROUPS Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762574057P | 2017-10-18 | 2017-10-18 | |
US201762608897P | 2017-12-21 | 2017-12-21 | |
US201862727316P | 2018-09-05 | 2018-09-05 | |
PCT/US2018/056311 WO2019079469A1 (fr) | 2017-10-18 | 2018-10-17 | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma |
Publications (2)
Publication Number | Publication Date |
---|---|
MA50398A true MA50398A (fr) | 2021-05-05 |
MA50398B1 MA50398B1 (fr) | 2021-10-29 |
Family
ID=64110207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA50398A MA50398B1 (fr) | 2017-10-18 | 2018-10-17 | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma |
Country Status (33)
Country | Link |
---|---|
US (3) | US10738057B2 (fr) |
EP (2) | EP4006034A1 (fr) |
JP (2) | JP7244504B2 (fr) |
KR (1) | KR20200089264A (fr) |
CN (2) | CN111542526B (fr) |
AU (2) | AU2018350980B2 (fr) |
BR (1) | BR112020007593A2 (fr) |
CA (1) | CA3084589A1 (fr) |
CL (1) | CL2020001047A1 (fr) |
CR (2) | CR20200214A (fr) |
CY (1) | CY1124814T1 (fr) |
EC (1) | ECSP20024651A (fr) |
ES (1) | ES2902390T3 (fr) |
GE (1) | GEP20237483B (fr) |
HR (1) | HRP20211827T1 (fr) |
HU (1) | HUE056615T2 (fr) |
IL (3) | IL295978B2 (fr) |
JO (1) | JOP20200086A1 (fr) |
LT (1) | LT3697789T (fr) |
MA (1) | MA50398B1 (fr) |
MD (1) | MD3697789T2 (fr) |
MX (1) | MX2020003862A (fr) |
PE (1) | PE20210169A1 (fr) |
PH (1) | PH12020550442A1 (fr) |
PL (1) | PL3697789T3 (fr) |
PT (1) | PT3697789T (fr) |
RS (1) | RS62818B1 (fr) |
SG (1) | SG11202003428VA (fr) |
SI (1) | SI3697789T1 (fr) |
TW (2) | TWI834560B (fr) |
UA (1) | UA128085C2 (fr) |
WO (1) | WO2019079469A1 (fr) |
ZA (1) | ZA202201220B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018350980B2 (en) | 2017-10-18 | 2023-02-23 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors |
EP4151641A1 (fr) | 2017-12-19 | 2023-03-22 | Turning Point Therapeutics, Inc. | Composés macrocycliques pour le traitement du cancer |
HUE057970T2 (hu) * | 2018-03-08 | 2022-06-28 | Incyte Corp | Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok |
GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
LT3847175T (lt) * | 2018-09-05 | 2024-03-25 | Incyte Corporation | Fosfoinozitido 3-kinazės (pi3k) inhibitoriaus kristalinės formos |
CN115286521B (zh) * | 2022-07-11 | 2023-11-03 | 上海医药集团(本溪)北方药业有限公司 | 一种盐酸左沙丁胺醇的合成方法 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4269846A (en) | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
IL153231A0 (en) | 2000-06-28 | 2003-07-06 | Smithkline Beecham Plc | Wet milling process |
IL160915A0 (en) | 2001-09-19 | 2004-08-31 | Aventis Pharma Sa | Indolizines inhibiting kinase proteins |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
MXPA04003954A (es) | 2001-10-26 | 2004-11-29 | Aventis Pharma Inc | Bencimidazoles. |
RU2337692C3 (ru) | 2001-10-30 | 2020-11-09 | Новартис Аг | Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3 |
DE10207843A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
EP1599474B1 (fr) | 2003-03-04 | 2013-04-24 | California Institute Of Technology | Composés oligomères hétérocycliques pour reconnaissance d'ADN |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP2007501189A (ja) | 2003-08-01 | 2007-01-25 | ジェネラブス テクノロジーズ,インコーポレイテッド | フラビウイルス科に対する二環式イミダゾール誘導体 |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
UA83509C2 (en) * | 2003-10-15 | 2008-07-25 | Оси Фармасьютикалз, Инк. | Imidazopyrazines as tyrosine kinase inhibitors |
WO2005118580A2 (fr) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Composes tricycliques utiles comme inhibiteurs du mecanisme de signalisation hypoxique |
ES2396135T3 (es) | 2004-06-10 | 2013-02-19 | Irm Llc | Compuestos y composiciones como inhibidores de proteínas cinasas |
EP1885352A2 (fr) | 2004-11-24 | 2008-02-13 | Novartis AG | Combinaisons d'inhibiteurs de kinase jak et d'au moins un inhibiteur de kinases bcr-abl, flt-3, fak et raf |
WO2007019417A1 (fr) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Dérivés d’oxazolopyridine comme modulateurs du sirtuin |
TW200800213A (en) | 2005-09-02 | 2008-01-01 | Abbott Lab | Novel imidazo based heterocycles |
BRPI0713328A2 (pt) | 2006-06-22 | 2012-10-30 | Biovitrum Ab | derivados de piridina e pirazina como inibidores de cinase mnk |
CA2681813A1 (fr) | 2007-03-27 | 2009-01-08 | Paratek Pharmaceuticals, Inc. | Composes modulant le facteur de transcription et leurs procedes d'utilisation |
DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
EA020777B1 (ru) | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
JP2011507851A (ja) | 2007-12-19 | 2011-03-10 | ザ スクリプス リサーチ インスティチュート | Rhoキナーゼインヒビターとしてのベンゾイミダゾールおよびアナログ |
US8623347B2 (en) | 2008-01-15 | 2014-01-07 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
US8329697B2 (en) | 2008-02-26 | 2012-12-11 | Merck Sharp & Dohme Corp. | Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors |
TWI444382B (zh) | 2008-03-11 | 2014-07-11 | Incyte Corp | 作為jak抑制劑之氮雜環丁烷及環丁烷衍生物 |
AR071523A1 (es) | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
WO2009158118A2 (fr) | 2008-05-30 | 2009-12-30 | University Of Notre Dame Du Lac | Agents antibactériens produits à partir d'échafaudages benzo[d]hétérocycliques utilisés pour prévenir et traiter une bactérie multirésistante aux antibiotiques |
US8470819B2 (en) | 2008-11-03 | 2013-06-25 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
WO2010061903A1 (fr) | 2008-11-27 | 2010-06-03 | 塩野義製薬株式会社 | Dérivé de pyrimidine et dérivé de pyridine présentant tous deux une activité inhibitrice de pi3k |
GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
WO2010135014A1 (fr) | 2009-02-27 | 2010-11-25 | Vertex Pharmaceuticals Incorporated | Inhibiteurs tricycliques de pyrazolopyridine kinase |
CA2756759C (fr) * | 2009-04-16 | 2017-11-07 | Joaquin Pastor Fernandez | Imidazopyrazines pour une utilisation en tant qu'inhibiteurs de kinase |
ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Pi3k 저해물질로서의 피리미디논 |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
WO2011075643A1 (fr) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k |
TW201130842A (en) | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
WO2011099832A2 (fr) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
TWI766281B (zh) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
JP2013523766A (ja) | 2010-03-31 | 2013-06-17 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのイミダゾリル‐イミダゾール |
JP5816678B2 (ja) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションIncyte Corporation | PI3Kδ阻害剤としての縮合誘導体 |
EP2575866A4 (fr) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | Inhibiteurs de ns5a du vhc |
EP2627650A2 (fr) | 2010-05-26 | 2013-08-21 | Merck Sharp & Dohme Corp. | Inhibiteurs n-phénylimidazolecarboxamides de la protéine kinase 3-phosphoinositide-dépendante de type 1 |
WO2011163195A1 (fr) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Dérivés condensés de pyrrole en tant qu'inhibiteurs de pi3k |
SG189396A1 (en) | 2010-10-13 | 2013-05-31 | Millennium Pharm Inc | Heteroaryls and uses thereof |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
US8729102B2 (en) | 2010-11-30 | 2014-05-20 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン |
WO2012125629A1 (fr) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Dérivés diamino-pyrimidines et diamino-pyridines substituées en tant qu'inhibiteurs de pi3k |
US8673905B2 (en) | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
KR20140093610A (ko) | 2011-04-21 | 2014-07-28 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
EP2718279B1 (fr) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Composés nouveaux comme modulateurs de la gpr119 |
EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
WO2013033569A1 (fr) | 2011-09-02 | 2013-03-07 | Incyte Corporation | Hétérocyclylamines en tant qu'inhibiteurs de pi3k |
US9260435B2 (en) | 2012-01-10 | 2016-02-16 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyrazines as Akt kinase inhibitors |
US9212169B2 (en) | 2012-03-01 | 2015-12-15 | Hyogo College Of Medicine | Benzimidazole derivative and use thereof |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
CN104334552B (zh) | 2012-05-31 | 2016-08-31 | 住友化学株式会社 | 稠合杂环化合物 |
BR112015000675B1 (pt) | 2012-07-13 | 2022-07-12 | UCB Biopharma SRL | Derivados de imidazopiridina como moduladores da atividade de tnf |
CN107936039A (zh) | 2012-11-01 | 2018-04-20 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
TWI687220B (zh) | 2013-03-01 | 2020-03-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
WO2014149207A2 (fr) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Compositions insecticides à base de benzimidazole et procédés apparentés |
US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
EP2976077A4 (fr) | 2013-03-22 | 2016-11-30 | Scripps Research Inst | Benzimidazoles substitués en tant que modulateurs d'un récepteur de nociceptine |
WO2014182954A1 (fr) | 2013-05-08 | 2014-11-13 | Colorado Seminary, Which Owns And Operates The University Of Denver | Agents antibiotiques et antiparasitaires qui modulent la fructose 1,6-bisphosphate aldolase de classe ii |
PL3786162T3 (pl) | 2013-05-17 | 2024-04-08 | Incyte Holdings Corporation | Pochodne bipirazolu jako inhibitory jak |
CN105408325B (zh) | 2013-07-17 | 2019-10-22 | 大塚制药株式会社 | 氰基三唑化合物 |
WO2015051241A1 (fr) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
CN106413716B (zh) | 2014-04-08 | 2020-03-27 | 因赛特公司 | 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤 |
EP2930048A1 (fr) | 2014-04-10 | 2015-10-14 | Johnson Controls Automotive Electronics SAS | Dispositif d'affichage tête haute projetant des informations visuelles sur un écran |
WO2015191677A1 (fr) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k |
CA2961525A1 (fr) | 2014-09-16 | 2016-03-24 | Celgene Quanticel Research, Inc. | Inhibiteurs de l'histone demethylase |
WO2016064957A1 (fr) * | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Composés amine hétéroaryles bicycliques utilisés comme inhibiteurs de la pi3k |
WO2016064958A1 (fr) * | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Composés pyrrolotriazine amine à substitution hétéroaryle en tant qu'inhibiteurs de pi3k |
MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
WO2016106624A1 (fr) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de la btk comprenant une imidazopyrazine d'alcool tertiaire |
US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
US9968604B2 (en) | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
CN107849036A (zh) | 2015-05-12 | 2018-03-27 | 卡利拉制药公司 | 二环化合物 |
AR106595A1 (es) | 2015-11-06 | 2018-01-31 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
US20170190689A1 (en) | 2016-01-05 | 2017-07-06 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
US10138248B2 (en) | 2016-06-24 | 2018-11-27 | Incyte Corporation | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors |
EP3505171A4 (fr) | 2016-08-26 | 2020-08-26 | Mitsubishi Tanabe Pharma Corporation | Composé hétérocyclique azoté bicyclique |
WO2018136754A1 (fr) | 2017-01-20 | 2018-07-26 | Massachusetts Institute Of Technology | Micro-dépôts polymères injectables pour administration locale contrôlée de médicament |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
RS65492B1 (sr) | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
KR20200101330A (ko) | 2017-10-18 | 2020-08-27 | 에피자임, 인코포레이티드 | Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물, 이의 염, 및 이들의 합성 방법 |
AU2018350980B2 (en) | 2017-10-18 | 2023-02-23 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors |
EP4151641A1 (fr) | 2017-12-19 | 2023-03-22 | Turning Point Therapeutics, Inc. | Composés macrocycliques pour le traitement du cancer |
CR20210307A (es) | 2017-12-21 | 2021-07-27 | Boehringer Ingelheim Int | NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312) |
UA127604C2 (uk) | 2017-12-21 | 2023-11-01 | Басф Се | Пестицидні сполуки |
LT3847175T (lt) | 2018-09-05 | 2024-03-25 | Incyte Corporation | Fosfoinozitido 3-kinazės (pi3k) inhibitoriaus kristalinės formos |
-
2018
- 2018-10-17 AU AU2018350980A patent/AU2018350980B2/en active Active
- 2018-10-17 TW TW112118992A patent/TWI834560B/zh active
- 2018-10-17 JP JP2020521911A patent/JP7244504B2/ja active Active
- 2018-10-17 LT LTEPPCT/US2018/056311T patent/LT3697789T/lt unknown
- 2018-10-17 KR KR1020207014142A patent/KR20200089264A/ko not_active Application Discontinuation
- 2018-10-17 CN CN201880081276.3A patent/CN111542526B/zh active Active
- 2018-10-17 TW TW107136622A patent/TWI803525B/zh active
- 2018-10-17 PT PT187974084T patent/PT3697789T/pt unknown
- 2018-10-17 ES ES18797408T patent/ES2902390T3/es active Active
- 2018-10-17 JO JOP/2020/0086A patent/JOP20200086A1/ar unknown
- 2018-10-17 BR BR112020007593-0A patent/BR112020007593A2/pt unknown
- 2018-10-17 CR CR20200214A patent/CR20200214A/es unknown
- 2018-10-17 PE PE2020000403A patent/PE20210169A1/es unknown
- 2018-10-17 MD MDE20200857T patent/MD3697789T2/ro unknown
- 2018-10-17 UA UAA202002916A patent/UA128085C2/uk unknown
- 2018-10-17 MX MX2020003862A patent/MX2020003862A/es unknown
- 2018-10-17 GE GEAP201815327A patent/GEP20237483B/en unknown
- 2018-10-17 US US16/163,341 patent/US10738057B2/en active Active
- 2018-10-17 CA CA3084589A patent/CA3084589A1/fr active Pending
- 2018-10-17 IL IL295978A patent/IL295978B2/en unknown
- 2018-10-17 CR CR20210442A patent/CR20210442A/es unknown
- 2018-10-17 EP EP21196484.6A patent/EP4006034A1/fr active Pending
- 2018-10-17 SI SI201830506T patent/SI3697789T1/sl unknown
- 2018-10-17 EP EP18797408.4A patent/EP3697789B1/fr active Active
- 2018-10-17 HR HRP20211827TT patent/HRP20211827T1/hr unknown
- 2018-10-17 RS RS20211581A patent/RS62818B1/sr unknown
- 2018-10-17 IL IL295978A patent/IL295978B1/en unknown
- 2018-10-17 WO PCT/US2018/056311 patent/WO2019079469A1/fr active Application Filing
- 2018-10-17 SG SG11202003428VA patent/SG11202003428VA/en unknown
- 2018-10-17 HU HUE18797408A patent/HUE056615T2/hu unknown
- 2018-10-17 CN CN202311732701.XA patent/CN118063470A/zh active Pending
- 2018-10-17 MA MA50398A patent/MA50398B1/fr unknown
- 2018-10-17 PL PL18797408T patent/PL3697789T3/pl unknown
-
2020
- 2020-04-16 IL IL273983A patent/IL273983B2/en unknown
- 2020-04-17 CL CL2020001047A patent/CL2020001047A1/es unknown
- 2020-04-17 PH PH12020550442A patent/PH12020550442A1/en unknown
- 2020-05-04 EC ECSENADI202024651A patent/ECSP20024651A/es unknown
- 2020-06-26 US US16/913,488 patent/US11225486B2/en active Active
-
2021
- 2021-11-30 US US17/537,674 patent/US11926630B2/en active Active
- 2021-12-03 CY CY20211101062T patent/CY1124814T1/el unknown
-
2022
- 2022-01-26 ZA ZA2022/01220A patent/ZA202201220B/en unknown
-
2023
- 2023-03-09 JP JP2023036727A patent/JP2023085290A/ja active Pending
- 2023-05-17 AU AU2023203088A patent/AU2023203088A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50398A (fr) | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma | |
MA45591A (fr) | Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs | |
MA56398A (fr) | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
TN2019000192A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
MA40301B1 (fr) | Composés indolecarboxamides utiles comme inhibiteurs de kinase | |
WO2016077464A8 (fr) | Dérivés d'acides aminés et leurs utilisations | |
BR112017017349A2 (pt) | composto, composição, método para tratar um distúrbio | |
EA201992873A1 (ru) | Получение фосфатных производных | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
MX2020010949A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas. | |
MA52891A (fr) | Dérivés aza-indoliques utilisés comme inhibiteurs de rho-kinase | |
EP3703692A4 (fr) | Nouveaux composés de tétrahydroquinoline substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) | |
EA201890476A1 (ru) | ЗАМЕЩЕННЫЕ 1,2-ДИГИДРО-3H-ПИРРОЛО[1,2-c]ИМИДАЗОЛ-3-ОНЫ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ | |
MA51285A (fr) | Dérivés d'azaindole comme inhibiteurs de rho-kinase | |
GEP20207130B (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
WO2016166720A3 (fr) | Polymorphes et procédé pour la préparation de dérivés de quinazolinyle | |
BR112021017661A2 (pt) | Uso de compostos 8,9-di-hidrocanabidiol | |
MX2019001781A (es) | Compuestos de tiofeno condensado utiles como inhibidores de napi-iib. | |
EP3694502A4 (fr) | Nouveaux composés cyclobutylbenzene substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) | |
EA201791645A1 (ru) | Новые соли и полиморфы scy-078 | |
MX2017009810A (es) | Derivado de nitroimidazol contra tuberculosis pulmonar. | |
PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
FR3056427B1 (fr) | Procede d'usinage par tournage d'une piece de turbomachine | |
EP3661910A4 (fr) | Nouveaux composés pyridine substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido) |